Is gabapentin addictive
Pro Research Analysisby 
Searched over 200M research papers
Gabapentin and Its Addictive Potential: A Comprehensive Review
Introduction to Gabapentin and Its Uses
Gabapentin, a medication primarily used to treat epilepsy and neuropathic pain, has seen a significant increase in prescriptions over the past decade. Despite its therapeutic benefits, concerns have emerged regarding its potential for misuse and addiction.
Gabapentin Misuse and Abuse
Prevalence and Patterns of Misuse
Several studies have documented the misuse of gabapentin, particularly among individuals with a history of substance use disorders (SUD). The prevalence of gabapentin misuse in the general population is relatively low, estimated at around 1.1% to 1.6% Evoy2017Mersfelder2016Smith2016. However, this rate is significantly higher among opioid abusers, ranging from 15% to 68% Evoy2017Smith2016. Misuse often involves taking higher-than-prescribed doses to achieve euphoric effects, similar to those of opioids and benzodiazepines Evoy2017Smith2016.
Risk Factors for Misuse
The primary risk factors for gabapentin misuse include a history of substance abuse, particularly opioids, and psychiatric comorbidities Evoy2017Mersfelder2016. Individuals with these risk factors are more likely to misuse gabapentin, often in combination with other substances such as opioids, benzodiazepines, and alcohol Evoy2017Smith2016.
Addiction Potential of Gabapentin
Evidence from Clinical Studies
The addiction potential of gabapentin appears to be relatively low, especially when compared to traditional substances of abuse. Most cases of gabapentin addiction have been reported in individuals with a history of other substance use disorders Bonnet2017Mersfelder2016Bonnet2016. In the general population, there is limited evidence of gabapentin causing significant behavioral dependence or leading to treatment-seeking behavior for addiction Bonnet2017Bonnet2021Bonnet2016.
Comparison with Pregabalin
Pregabalin, a related gabapentinoid, has been found to have a higher potential for addiction compared to gabapentin. This is evidenced by more frequent reports of behavioral dependence, transitions from prescription to self-administration, and higher rates of misuse among individuals with SUD Bonnet2017Bonnet2017Chiappini2016. Pregabalin's quicker absorption and higher bioavailability may contribute to its higher addictive potential Chiappini2016Schifano2014.
Withdrawal and Dependence
Physical Dependence and Withdrawal Symptoms
Physical dependence on gabapentin can develop, particularly with long-term use or high doses. Withdrawal symptoms, which can occur within 12 hours to 7 days of discontinuation, include anxiety, agitation, and other symptoms similar to those seen with benzodiazepine withdrawal Mersfelder2016Bonnet2016. However, these symptoms are generally manageable and less severe than those associated with other addictive substances Mersfelder2016Bonnet2016.
Behavioral Dependence
Behavioral dependence on gabapentin is rare, with very few cases reported in individuals without a history of other substance use disorders Bonnet2017Bonnet2021Bonnet2018. This suggests that gabapentin's addictive potential is relatively low in the general population, although it can be higher in those with pre-existing SUD Bonnet2017Bonnet2021Bonnet2018.
Conclusion
In summary, while gabapentin does have some potential for misuse and addiction, particularly among individuals with a history of substance use disorders, its overall addictive potential is relatively low. Pregabalin, on the other hand, appears to have a higher risk of addiction. Healthcare providers should be vigilant when prescribing gabapentin, especially to patients with a history of substance abuse, and should monitor for signs of misuse and dependence.
Sources and full results
Most relevant research papers on this topic
How addictive are gabapentin and pregabalin? A systematic review.
Gabapentinoids show limited addictive power, with pregabalin being more addictive, and should be avoided or administered with caution in patients with substance use disorders.
DOI